Description: <b>CUSP9 </b>coordinated undermining of survival paths with nine repurposed drugs<br>
-includes aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, sertraline, ritonavir<br>
<br>
<p><b>CUSP9</b> — CUSP9 is a coordinated multi-drug repurposing regimen for glioblastoma built around the concept of Coordinated Undermining of Survival Paths. It is a polypharmacologic adjunct oncology protocol rather than a single molecular entity, formally classified as a multi-agent drug-repurposing regimen used with low-dose metronomic temozolomide in the clinically tested CUSP9v3 version. Standard abbreviations include CUSP9, CUSP9*, and CUSP9v3. The regimen originated from the International Initiative for Accelerated Improvement of Glioblastoma Care and subsequent Ulm University clinical development. The Nestronics PID 296 entry is accessible but contains only one listed reference, so it should be treated as low-weight for mechanistic detail.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Multi-pathway blockade of glioblastoma survival, invasion, inflammation, redox adaptation, efflux, and compensatory resistance networks.</li>
<li>Redox stress amplification through thioredoxin reductase inhibition, ALDH inhibition, ROS generation, and impaired detoxification capacity.</li>
<li>Temozolomide augmentation through resistance-pathway suppression, metronomic alkylator pressure, and reduced adaptive escape rather than a single direct chemosensitizing target.</li>
<li>Invasion and microenvironment suppression through angiotensin, MMP, COX-2, microglial, cytokine, and inflammatory axes.</li>
<li>Drug transport and exposure modulation through P-gp, BCRP, CYP, and BBB-relevant pharmacology, with both therapeutic and toxicity implications.</li>
<li>Apoptosis and mitochondrial stress, particularly in CUSP9v3 combinations and in vitro TTFields plus CUSP9v3 experiments.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> CUSP9 is orally administered and highly PK-constrained because it combines multiple approved drugs with different half-lives, CNS penetration, protein binding, hepatic metabolism, and CYP or transporter effects. CUSP9v3 specifically requires careful dose escalation and monitoring because ritonavir, itraconazole, aprepitant, celecoxib, sertraline, and other components create clinically meaningful interaction potential. BBB exposure is component-specific and may not scale linearly with plasma exposure.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> CUSP9 is concentration-driven, but the clinically relevant question is not the exposure of one drug alone; it is whether simultaneous low-to-moderate exposure across multiple repurposed agents can suppress glioblastoma escape pathways. Some in-vitro work used clinically oriented fixed concentrations, but sensitivity is model-dependent, and lower-order subsets may match or exceed the full nine-drug cocktail in some patient-derived cultures. Translation should therefore treat in-vitro efficacy as supportive, not definitive.</p>
<p><b>Clinical evidence status:</b> Preclinical rationale is extensive and includes multiple in-vitro glioblastoma and glioma stem-like cell studies. Human evidence is small but real: compassionate-use experience and a phase Ib/IIa recurrent glioblastoma trial support feasibility and tolerability under careful monitoring. Efficacy remains unproven because randomized outcome data are not yet available. CUSP9/CUSP9v3 is not an approved oncology regimen; its components are approved for other indications.</p>
<h3>CUSP9 cancer mechanism table</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Multi-pathway survival network blockade</td>
<td>Parallel GBM survival routes ↓; compensatory escape ↓; heterogeneity buffering ↓</td>
<td>Broad off-target burden possible; toxicity depends on cumulative dose and interactions</td>
<td>G</td>
<td>Resistance-network suppression</td>
<td>Core identity of CUSP9; strongest conceptual rationale is simultaneous weak-to-moderate pressure across many GBM survival axes rather than a dominant single target.</td>
</tr>
<tr>
<td>2</td>
<td>Redox detoxification and thioredoxin axis</td>
<td>Thioredoxin reductase ↓; ALDH ↓; ROS ↑; apoptotic susceptibility ↑</td>
<td>Redox reserve may be stressed; hepatic and hematologic monitoring relevant</td>
<td>R/G</td>
<td>Pro-oxidant tumor stress</td>
<td>Auranofin and disulfiram are central contributors. This is one of the clearest mechanistic pressure points in CUSP9v3.</td>
</tr>
<tr>
<td>3</td>
<td>Temozolomide resistance and chemosensitization</td>
<td>Adaptive survival pathways ↓; TMZ escape capacity ↓; alkylator pressure maintained</td>
<td>Myelosuppression and cumulative tolerability remain limiting</td>
<td>G</td>
<td>Adjunct chemosensitization</td>
<td>CUSP9v3 was clinically tested with continuous low-dose metronomic temozolomide. Some in-vitro data found limited added benefit from TMZ under specific conditions, so this row is clinically important but mechanistically model-dependent.</td>
</tr>
<tr>
<td>4</td>
<td>Invasion and extracellular matrix remodeling</td>
<td>MMP-2 ↓; MMP-9 ↓; migration ↓; invasion ↓</td>
<td>Normal inflammatory and wound-remodeling processes may also be affected</td>
<td>G</td>
<td>Anti-invasive activity</td>
<td>Captopril and minocycline in CUSP9v3 are most relevant; original and variant CUSP9 compositions differ, so component-specific interpretation is required.</td>
</tr>
<tr>
<td>5</td>
<td>Inflammatory COX and prostaglandin signaling</td>
<td>COX-2 ↓; PGE2-linked proliferation and inflammatory support ↓</td>
<td>GI, renal, cardiovascular, and blood pressure risks are clinically relevant</td>
<td>G</td>
<td>Inflammatory support suppression</td>
<td>Celecoxib contributes anti-inflammatory and possible carbonic anhydrase-linked effects, but clinical leverage depends on tolerability and patient risk profile.</td>
</tr>
<tr>
<td>6</td>
<td>NK-1 substance P signaling</td>
<td>NK-1 signaling ↓; proliferation and pro-survival signaling ↓</td>
<td>Generally tolerable, but CYP interaction context matters</td>
<td>G</td>
<td>Growth signal suppression</td>
<td>Aprepitant is included for NK-1 receptor inhibition and supportive antiemetic pharmacology; its oncology role remains adjunctive and not independently validated as a GBM therapy.</td>
</tr>
<tr>
<td>7</td>
<td>Drug efflux and BBB exposure</td>
<td>P-gp/BCRP-linked efflux ↓ or altered; intracellular drug exposure may ↑</td>
<td>Systemic drug exposure and interaction risk may ↑</td>
<td>R/G</td>
<td>Exposure modulation</td>
<td>Itraconazole, ritonavir, and sertraline can alter transporter or CYP-linked exposure. This can be therapeutically useful but is also a major safety constraint.</td>
</tr>
<tr>
<td>8</td>
<td>PI3K AKT mTOR and TCTP signaling</td>
<td>AKT/mTOR survival tone ↓; TCTP-linked survival signaling ↓</td>
<td>Context-dependent effects on metabolism, mood, and systemic signaling</td>
<td>G</td>
<td>Growth and survival suppression</td>
<td>Sertraline and ritonavir are relevant contributors. This is a secondary but mechanistically meaningful survival-axis target.</td>
</tr>
<tr>
<td>9</td>
<td>Hedgehog autophagy and sterol-linked signaling</td>
<td>Hedgehog/autophagy programs ↓; adaptive survival ↓</td>
<td>Hepatic toxicity and CYP3A4 interactions are important</td>
<td>G</td>
<td>Adaptive pathway suppression</td>
<td>Itraconazole is a key component, but this axis is limited by drug interaction and hepatic monitoring requirements.</td>
</tr>
<tr>
<td>10</td>
<td>Mitochondrial apoptosis and oxidative phosphorylation</td>
<td>MOMP ↓; caspase-3 cleavage ↑; Bcl-2/Mcl-1 ↓; OXPHOS ↓</td>
<td>Potential mitochondrial stress is context-dependent</td>
<td>R/G</td>
<td>Apoptosis promotion</td>
<td>Especially supported by recent TTFields plus CUSP9v3 in-vitro work, where combined treatment enhanced apoptosis and reduced respiratory chain activity.</td>
</tr>
<tr>
<td>11</td>
<td>Glioma stem-like phenotype and tumor sphere formation</td>
<td>Sphere formation ↓; stem-like viability ↓; migration ↓</td>
<td>Normal neural progenitor relevance uncertain</td>
<td>G</td>
<td>Stem-like compartment suppression</td>
<td>Reported in preclinical glioblastoma stem-like models, with heterogeneous response across cultures and possible subtype dependence.</td>
</tr>
<tr>
<td>12</td>
<td>Clinical Translation Constraint</td>
<td>Potential benefit depends on simultaneous pathway pressure, tumor subtype, and achievable exposure</td>
<td>Dose limitation, hepatic enzymes, GI effects, neurologic symptoms, CYP interactions, BBB variability, and adherence burden are major constraints</td>
<td>G</td>
<td>Feasibility and safety limitation</td>
<td>Human evidence supports careful monitored administration, not routine efficacy. The regimen is complex and should be treated as investigational.</td>
</tr>
</table>
<p>TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr</p>